Dymon Asia Capital »

Trevi Therapeutics shares owned by Dymon Asia Capital

Quarter-by-quarter ownership of Trevi Therapeutics (TRVI) shares owned by Dymon Asia Capital from 13F filings

Historical chart of Dymon Asia Capital investment in Trevi Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Trevi Therapeutics held by Dymon Asia Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Trevi Therapeutics by Dymon Asia Capital

Quarter filed Position value Share count Share price at filing
2025-12-31 $250k 20k 12.52

More positions owned by Dymon Asia Capital

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Silver Tr Ishares Call Option (SLV)
NVIDIA Corporation (NVDA)
Ishares Tr Mbs Etf (MBB)
Meta Platforms Cl A Call Option (META)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Microsoft Corporation (MSFT)
Broadcom (AVGO)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Home Depot (HD)
Qualcomm (QCOM)
Synopsys Call Option (SNPS)
Spdr Gold Tr Gold Shs Call Option (GLD)
Alphabet Cap Stk Cl A (GOOGL)
Taiwan Semiconductor Mfg Sponsored Ads (TSM)

View all positions for Dymon Asia Capital

Top funds holding Trevi Therapeutics

NEA Management Company
Frazier Life Sciences Management
BlackRock
Vanguard Group
Vivo Capital
Marshall Wace
Alliancebernstein
Rubric Capital Management
FMR
MPM Oncology Impact Management
Wellington Management Company
Viking Global Investors
OrbiMed Advisors
Octagon Capital Advisors
Eventide Asset Management

View all funds holding Trevi Therapeutics